Contains Proteins Or Derivative Or Polysaccharides Or Derivative Patents (Class 424/499)
  • Patent number: 11903966
    Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: February 20, 2024
    Assignees: REGENTS OF THE UNIVERSITY OF MINNESOTA, INTIMA BIOSCIENCE, INC., The U.S.A., as represented by the Secretary, Department f Health and Human Services
    Inventors: Branden Moriarity, Beau Webber, Modassir Choudhry, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
  • Patent number: 11850323
    Abstract: A solidifying prepolymeric implant composition comprising a biocompatible prepolymer and an optional filler. One such implant composition is a polyurethane implant composition comprising an isocyanate, such as hydroxymethylenediisocyanate (HMDI) and an alcohol, such as polycaprolactonediol (PCL diol). The compositions of the invention are useful for improving bone structure in patients by applying the solidifying implant composition to bone, reinforcing bone structure, improving load bearing capacity and/or aiding healing of microfractures.
    Type: Grant
    Filed: December 7, 2020
    Date of Patent: December 26, 2023
    Assignee: 206 ORTHO, INC.
    Inventors: Jeffrey A. D'Agostino, Andrew J. Carter, Craig M. Jones, Arthur C. Watterson
  • Patent number: 11821892
    Abstract: The present invention provides oxygenized nanobubbles and their uses in imaging and cancer treatment when combined with therapeutic drugs and precise ultrasound beam steering.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: November 21, 2023
    Assignee: Purdue Research Foundation
    Inventors: Joseph Irudayaraj, Pushpak Bhandari
  • Patent number: 11786471
    Abstract: A complex disintegrant composition for oral solid preparation, comprising a disintegrant and a disintegrating aid, the disintegrant being a hygroscopic expansion type disintegrant, the disintegrating aid being a soluble small molecule substance or a gas-producing type salt. An oral solid preparation, comprising an active ingredient, said complex disintegrant composition, an excipient and a lubricant.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: October 17, 2023
    Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD.
    Inventors: Yaowen Wan, Yongkai Chen, Xian Zeng, Chaodong Wang, Wei Feng
  • Patent number: 11655469
    Abstract: Disclosed herein are methods of treating a tumor in a subject, including administering to the subject one or more miRNA nucleic acids or variants (such as mimics or mimetics) thereof with altered expression in the tumor. Also disclosed herein are compositions including one or more miRNA nucleic acids. In some examples, the miRNA nucleic acids are modified miRNAs, for example, and miRNA nucleic acid including one or more modified nucleotides and/or a 5?-end and/or 3?-end modification. In particular examples, the modified miRNA nucleic acid is an miR-30a nucleic acid. Further disclosed herein are methods of diagnosing a subject as having a tumor with altered expression of one or more miRNA nucleic acids. In some embodiments, the methods include detecting expression of one or more miRNAs in a sample from the subject and comparing the expression in the sample from the subject to a control.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: May 23, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, miRenlo, Inc.
    Inventors: Anthony D. Saleh, Carter Van Waes, Zhong Chen, Hui Cheng
  • Patent number: 11617815
    Abstract: Various aspects described herein relate to compositions comprising silk fibroin particles and methods of using the same, as well as devices and methods of delivering such compositions. The compositions described herein are suitable for injection into a site of defect in a soft tissue to provide bulking and/or augmentation effect to the soft tissue.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: April 4, 2023
    Assignee: Sofregen Medical, Inc.
    Inventors: Anh Hoang-Lindsay, Christopher P. Gulka, Jodie E. M. Giordano, Joseph E. Brown, Thomas L. Carroll
  • Patent number: 11612568
    Abstract: The invention relates to a method for making a tablet having a diameter, as determined by the longest enveloping circle, in the range of 1 to 5 mm and/or a weight in the range of 1 to 100 mg—comprising an active ingredient selected from the group of pharmaceutical substances and active substances for a dietary supplement or nutraceutical, comprising (a) providing a lactose agglomerate comprising lactose, and a sugar alcohol; (b) providing the active ingredient; (c) mixing the agglomerate and the active ingredient, thereby obtaining a mixture; and (d) forming the tablet by direct compression.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: March 28, 2023
    Assignee: DFE PHARMA GMBH & CO. KG
    Inventors: Korinde Van Den Heuvel, Bas Van Laarhoven, Eva Maria Janssen, Mara Maria Wilhelmina Van Haandel
  • Patent number: 11607407
    Abstract: The present invention is directed to therapeutic pharmaceutical compositions of 1-Methyl-2?, 6?-pipecoloxylidide or it pharmaceutically acceptable salts for application to the skin and the use thereof.
    Type: Grant
    Filed: April 13, 2011
    Date of Patent: March 21, 2023
    Assignee: Relmada Therapeutics, Inc.
    Inventor: Najib Babul
  • Patent number: 11590253
    Abstract: A composite material is formed by combining an expandable polymer having a charge with another polymer having an opposite charge to produce. In particular, the composite material can be prepared by combining the polymers with a medium such as and water, and expanding the mixture using a treatment that expands the mixture to produce, for example, insoluble porous foam-like composites.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: February 28, 2023
    Assignee: The Penn State Research Foundation
    Inventors: Jeffrey Catchmark, Yuzhi Deng
  • Patent number: 11547746
    Abstract: The present invention relates to a method for preventing and/or treating coronary atherosclerosis and its related conditions in a subject, comprising administering a prophylactically and/or therapeutically effective amount of plasminogen to the subject, wherein the subject suffers from, is suspected of suffering from coronary atherosclerosis and its related conditions, or has a risk of suffering from coronary atherosclerosis and its related conditions. The present invention further relates to a medicament, a pharmaceutical composition, an article of manufacture, and a kit comprising plasminogen which are useful for preventing and/or treating coronary atherosclerosis and its related conditions in a subject.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: January 10, 2023
    Assignee: Talengen International Limited
    Inventor: Jinan Li
  • Patent number: 11548946
    Abstract: Described herein are compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of binding agents and carrier proteins, and optionally at least one therapeutic agent, and methods of making and using the same, in particular, as a cancer therapeutic. Still also described are methods for treating and/or increasing the therapeutic effectiveness of an immunotherapy of a patient suffering from a cancer which expresses PD-L1 or PD-L2 by administering to the patient a nanoparticle composition and a PD-1 immunotherapy.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: January 10, 2023
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11541011
    Abstract: A composition in powder form comprising alginic acid or sodium alginate, -pectin and chitosan, wherein the % by weight of the polysaccharides is at least 20% with respect to the total weight of the powder, the process for preparing the powder and its use in the treatment of cutaneous wounds and in the sector of food preservation are described.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: January 3, 2023
    Assignee: MATERIAS S.r.l.
    Inventors: Pasquale Del Gaudio, Rita Patrizia Aquino, Paola Russo, Gianluigi De Falco, Luigi Nicolais
  • Patent number: 11534421
    Abstract: A pouch designed for administration of an active ingredient in the oral cavity is disclosed, the pouch containing a matrix composition having a combination of an amount of one or more cannabinoids and a water-insoluble composition. Also, pouches for use as a medicament, for use in alleviation of pain, and for use in mitigation of appetite deficiency are disclosed. Further, a method of alleviation of pain and a method of mitigation of appetite deficiency using the pouch are disclosed.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: December 27, 2022
    Inventor: Heidi Ziegler Bruun
  • Patent number: 11491090
    Abstract: The present invention relates to compositions of spherical microparticles composed of a wall material and at least one cavity that comprises a gas and/or a liquid, which have pores on the surface thereof, wherein the spherical microparticles have a mean particle diameter of 10-600 ?m and wherein at least 80% of those microparticles, the particle diameter of which does not deviate from the mean particle diameter of the microparticles of the composition by more than 20%, each have on average at least 10 pores, the diameter of which is in the range from 1/5000 to ? of the mean particle diameter, and, furthermore, the diameter of each of these pores is at least 20 nm, wherein the wall material consists of a composition comprising at least one aliphatic-aromatic polyester, and the wall material has a solubility at 25° C. of at least 50 g/l in dichloromethane, a method for the preparation thereof and also the use thereof.
    Type: Grant
    Filed: October 4, 2017
    Date of Patent: November 8, 2022
    Inventors: Ewelina Burakowska-Meise, Wolfgang Krause, Patrick Leibach, Karl Kolter
  • Patent number: 11466057
    Abstract: It has been found that an extracellular polypeptide derived from Akkermansia municiphila is capable of modulating and/or promoting gut mucosal immune system function and/or maintaining and/or restoring metabolic status and/or increasing the physical integrity of the gut mucosal barrier in a mammal. The polypeptide or host cells comprising such polypeptide may be employed to prevent and/or treat a variety of conditions that benefit from an increased physical integrity of the gut mucosal barrier and/or an improved gut mucosal immune system function and metabolic status.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignees: WAGENINGEN UNIVERSITEIT, UNIVERSITÉ CATHOLIQUE DE LOUVAIN
    Inventors: Clara Belzer, Willem Meindert De Vos, Patrice Daniel Cani
  • Patent number: 11427637
    Abstract: Described herein are methods, formulations and kits for treating a patient with cancer with nanoparticle complexes comprising a carrier protein, a binding agent and paclitaxel and optionally co-treated with an anti-PD-L1 antibody.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: August 30, 2022
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 11331270
    Abstract: The present application relates to a pharmaceutical composition in a form of dry powder for intranasal administration, comprising solid particles of at least one active agent and solid particles of a diluent, said pharmaceutical composition being substantially free of excipients other than the solid diluent, wherein said pharmaceutical composition having at least 90% of the particles of said at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of said at least one active agent with a mean particle size equal to or below 5 microns. The particles of said diluent have a mean particle size of 30-200 microns. The present application also relates to an apparatus and modified spray drying method for preparation of the pharmaceutical composition of the present invention in the dry powder form.
    Type: Grant
    Filed: August 19, 2018
    Date of Patent: May 17, 2022
    Assignee: Nasus Pharma Ltd.
    Inventor: Galia Temtsin-Krayz
  • Patent number: 11319367
    Abstract: Disclosed herein are methods of reducing a symptom of respiratory disease in a pre-weaned milk-fed mammal by orally administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Also included are methods of reducing mixing stress in human and non-human mammals by administering an isolated antibody that specifically binds the interleukin-10 peptide or an anti-interleukin-10 antibody. Further included are milk and food compositions including the interleukin-10 peptide or anti-interleukin-10 antibody.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: May 3, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark Eric Cook, Jordan Marshall Sand, Sheila Mary McGuirk, Jane Ellen Rieman, Sarah Marie Raabis
  • Patent number: 11260025
    Abstract: An in situ gelling composition comprising nanoparticles comprising soy protein and a bioactive agent, and a sodium alginate film, wherein the nanoparticles are encapsulated in the film. The in situ gelling composition maybe incorporated into a solid dosage form or reconstituted with water for oral administration to a subject in need of sustained release of the bioactive agent.
    Type: Grant
    Filed: February 15, 2021
    Date of Patent: March 1, 2022
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Shadab MD, Samaa T. Abdullah, Nabil A. Alhakamy
  • Patent number: 11260359
    Abstract: The microcapsules and process of making describe a novel core shell microcapsule. The microcapsule incorporates a polysaccharide such as chitosan into the microcapsule wall forming the shell. The microcapsule shell is formed by dissolving chitosan into a material of structure wherein each R is independently selected from hydrogen, C1 to C8 alkyl, or a cyano group; and each y is independently an integer from 1 to 8, and reacting with a multifunctional (meth)acrylate.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 1, 2022
    Inventors: Presley Genevie Neuman, Linsheng Feng
  • Patent number: 11202757
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles. A naloxone pharmaceutical composition in the form of dry powder for intranasal administration, including as active agent naloxone or a pharmaceutically acceptable salt thereof. A kit for intranasal administration of naloxone. A method of treating opioid overdose/intoxication and/or a symptom thereof in a patient in need thereof by intranasally administering a therapeutically effective amount of a composition including solid particles of at least one opioid receptor antagonist as active ingredient and two types of solid particles.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: December 21, 2021
    Assignee: Formulex Pharma Innovations Ltd.
    Inventors: Galia Temtsin-Krayz, Dalia Megiddo, Tair Lapidot, Carolina Abrutzky
  • Patent number: 11202766
    Abstract: Novel hydrocodone bitartrate and guaifenesin pharmaceutical compositions. Methods of making and using the hydrocodone bitartrate and guaifenesin pharmaceutical compositions also are disclosed.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: December 21, 2021
    Assignee: ECI Pharmaceuticals, LLC
    Inventors: Solomon Goll, Nirali R. Bhatt
  • Patent number: 11185122
    Abstract: Sports boot element comprising all or part of a wall designed to form at least part of a lateral and/or frontal and/or rear and/or lower wall of a sports boot, characterised in that all or part of its wall comprises a material (10) comprising a polymer (11) and a hollow microball (12) filler.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: November 30, 2021
    Assignee: ROSSIGNOL LANGE S.R.L.
    Inventor: Matteo Stefan
  • Patent number: 11185093
    Abstract: The present invention relates to pulverulent compositions of at least one carotenoid selected from the group consisting of ?-carotene, astaxanthin, canthaxanthin, citranaxanthin, lycopene and lutein, a process for the production of these pulverulent compositions, and the use of the pulverulent compositions.
    Type: Grant
    Filed: November 11, 2008
    Date of Patent: November 30, 2021
    Inventor: Christian Köpsel
  • Patent number: 11179414
    Abstract: Disclosed is a method for producing a protease degradation composition by degrading a composition containing a hyaluronic acid and a protein with a protease, in the presence of an ascorbic acid, an ascorbate or a salt thereof. The composition produced according to the method has a high fibroblast proliferation promoting effect and a high collagen production promoting effect.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: November 23, 2021
    Assignee: LAIMU CORPORATION
    Inventor: Sachio Wakayama
  • Patent number: 11154570
    Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: October 26, 2021
    Assignee: Particle Dynamics International, LLC.
    Inventors: Paul Brady, Keith Cromack
  • Patent number: 11116723
    Abstract: A pharmaceutical composition in a form of dry powder for intranasal administration includes solid particles of at least one active agent and solid particles of a diluent. The pharmaceutical composition is substantially free of excipients other than the solid diluent. The pharmaceutical composition has at least 90% of the particles of the at least one active agent with a mean particle size of 10-30 microns and less than 10% of the particles of the at least one active agent with a mean particle size equal to or below 5 microns. The particles of the diluent have a mean particle size of 30-200 microns. An apparatus and method for preparation of the pharmaceutical composition utilize a spray-drying chamber, a cyclone separator, and a receiving chamber.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: September 14, 2021
    Assignee: Formulex Pharma Innovations Ltd.
    Inventor: Galia Temtsin-Krayz
  • Patent number: 11110151
    Abstract: An ultra-rapid acting insulin composition and method for treating hyperglycemia in patients with diabetes are disclose. The composition is an inhalable dry powder composition comprising fumaryl diketopiperazine and insulin for pulmonary delivery, which significantly reduces the rates of hypoglycemic events in patients in patients on mealtime insulin therapy.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 7, 2021
    Assignee: MannKind Corporation
    Inventors: Marshall Grant, Simon R. Bruce, Robert A. Baughman
  • Patent number: 11103501
    Abstract: A spray dried-powder composition for inhalation comprising particles (X) containing (a) between 5 and 50% by weight of at least one azole derivative in amorphous state but not in crystalline structure and (b) at least one matricial agent to the composition selected from a group consisting of polyol such as sorbitol, mannitol and xylitol; a monosaccharides such as glucose and arabinose; disaccharide such as lactose, maltose, saccharose and dextrose; cholesterol, and any mixture thereof, wherein the composition provides a dissolution rate of said azole derivative of at least, 5% within 10 minutes, 10% within 20 minutes and 40% within 60 minutes when tested in the dissolution apparatus type 2 of the United States Pharmacopoeia at 50 rotation per minute, 37° C. in 900 milliliters of an aqueous dissolution medium adjusted at pH 1.2 and containing 0.3% of sodium laurylsulfate.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: August 31, 2021
    Inventors: Arthur Deboeck, Francis Vanderbist, Philippe Baudier, Thami Sebti, Christophe Duret, Karim Amighi
  • Patent number: 11065238
    Abstract: The present invention relates to inhibitors of gangliosides metabolism for treating motor neuron diseases, in particular hereditary spastic paraplegias.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: July 20, 2021
    Assignees: ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE), SORBONNE UNIVERSITE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, APHP (ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS), ÉCOLE PRATIQUE DES HAUTES ÉTUDES
    Inventors: Frédéric Darios, Giovanni Stevanin, Fanny Mochel, Julien Branchu, Maxime Boutry
  • Patent number: 11045492
    Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 29, 2021
    Assignee: onCour Pharma, Inc.
    Inventor: John Puisis
  • Patent number: 11045464
    Abstract: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: June 29, 2021
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Patent number: 11033602
    Abstract: Disclosed herein is a pulmonary administration device, comprising a spray nozzle unit and a cartridge containing an aqueous solution comprising from 70 to 400 mg A/m L of a sulfomethylated polymyxin, and use of sulfomethylated polymyxin in a device for pulmonary administration in a patient in need thereof.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: June 15, 2021
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventor: Nenad Bencic
  • Patent number: 11013736
    Abstract: The invention discloses an oral solid preparation containing any one, or a mixture of two or more of crystalline form I, II, III, and IV of the compound represented by formula (A). The oral solid preparation of the present invention disintegrates rapidly, increasing dissolution rate thereof, thereby improving bioavailability. In particular, it is possible to solve the problem that an active material (active ingredient), which is high hygroscopic and becomes sticky after moisture absorption, can not be effectively disintegrated by conventional disintegrants. The present invention further relates to a use of the oral solid preparation in preparing an angiotensin II receptor antagonist or a use thereof in preparing medicine for preventing and/or treating hypertension, chronic heart failure and diabetic nephropathy.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: May 25, 2021
    Assignee: WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD.
    Inventors: Lei Liang, Yongkai Chen, Liu Hu, Wei Feng, Chaodong Wang
  • Patent number: 11007279
    Abstract: A major challenge in non-viral gene delivery remains finding a safe and effective delivery system. Colloidally stable non-viral gene vector delivery systems capable of overcoming various biological barriers, are disclosed. The gene vectors are biodegradable, non-toxic and highly tailorable for use in specific applications. The vectors include a mixture of biodegradable copolymers, such as PBAE, and biodegradable polymers conjugated with hydrophilic, neutrally charged polymer, such as PEG. The gene vectors demonstrate broad vector distribution and high transgene delivery in vivo, providing an efficient non-viral gene delivery system for localized therapeutic gene transfer. Methods of using the vectors to overcome biological barriers including mucus gel and extracellular matrix are provided. Methods of formulating the vectors are also provided.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 18, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Justin Hanes, Jung Soo Suk, Panagiotis Mastorakos
  • Patent number: 10993911
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10993912
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: May 4, 2021
    Assignee: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10912848
    Abstract: The present invention provides a dual-purpose photoacoustic tomography (PAT)/ultrasound contrast agent comprising: (a) a micro-bubble containing gas and porphyrin therein; and (b) nanoparticles bound on a surface of the micro-bubble and containing a drug. The contrast agent of the present invention can be used in both the ultrasound diagnosis and the photoacoustic image diagnosis, and can significantly increase the accuracy of photoacoustic images.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: February 9, 2021
    Assignee: IMGT CO, LTD.
    Inventors: Hyun Cheol Kim, Hyung Won Moon, Jin Ho Chang
  • Patent number: 10786486
    Abstract: Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.
    Type: Grant
    Filed: November 16, 2017
    Date of Patent: September 29, 2020
    Inventor: Vasilios Voudouris
  • Patent number: 10772833
    Abstract: Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: September 15, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10773231
    Abstract: This invention relates to a process for colloidosome-type microcapsules elaboration from solid particles microcapsules obtained by ionic gelation. In the process, an (O/W) type emulsion is initially generated stabilized with the solid particles microcapsules, and then the particles are fixed to the interface by adsorption of polyelectrolytes, cross-linking, heat treatment or fatty coating, generating the colloidosome with the water-insoluble phase encapsulated in the core and covered by the shell particles.
    Type: Grant
    Filed: June 18, 2016
    Date of Patent: September 15, 2020
    Assignees: Nexentia S.A.S., Universidad de Antioquia
    Inventors: Herley Casanova, César Augusto Pérez Zapata
  • Patent number: 10765741
    Abstract: This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., Abraxane®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: September 8, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Svetomir N. Markovic, Wendy K. Nevala
  • Patent number: 10751293
    Abstract: A multilayered polymer composite film includes a water-soluble polymer matrix and a plurality of fibers embedded within the water soluble polymer matrix. The fibers include a water insoluble polymer material and at least one of a non-polymeric hydrophobic therapeutic agent or a non-polymeric hydrophobic cosmetic agent incorporated in the water insoluble polymer material. The fibers have a rectangular cross-section, and extend the entire length of the multilayered polymer composite film.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: August 25, 2020
    Assignee: Case Western Reserve University
    Inventors: Eric Baer, Gary E. Wnek, Mohammad Mofidfar, Jia Wang
  • Patent number: 10711040
    Abstract: The present invention relates to novel low substituted polymyxins and compositions thereof.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: July 14, 2020
    Assignee: XELLIA PHARMACEUTICALS APS
    Inventors: Vidar Bjornstad, Solvi Gunnes, Torben Koch, Claes Melander
  • Patent number: 10617648
    Abstract: The present invention provides for method of improving flowability and loose bulk density of functionalized natural- and/or synthetic calcium carbonate comprising material, to the use of such improved material in ready to use granules and thereof produced dispersible dosage forms.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 14, 2020
    Assignee: Omya International AG
    Inventors: Leonie Wagner-Hattler, Maxim Puchkov, Jörg Huwyler, Tanja Stirnimann, Carolina Diaz Quijano, Joachim Schoelkopf, Patrick A. C. Gane, Daniel E. Gerard
  • Patent number: 10611908
    Abstract: Biocompatible block copolymer micelles for use in mucoadhesive drug delivery are provided. The micelles comprise a degradable hydrophobic polymer, a degradable synthetic hydrophilic polymer and a mucoadhesive polymer. The micelles are particularly useful for ophthalmic uses.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: April 7, 2020
    Assignee: McMaster University
    Inventors: Heather Sheardown, Graeme Prosperiporta, Stephanie Kedzior, Benjamin Muirhead
  • Patent number: 10568992
    Abstract: The present invention relates to the production of endothelialized matrices and materials from immature endothelial cells using substrates to which particular peptides have been grafted. The resultant substrates can be used to capture and support immature endothelial cells. Further, the methods and compositions of the present invention provide viable cell delivery platforms that allow for production and provision of endothelialized medical devices and implants, including vascular grafts, stents, shunts, and valves, endothelialized surfaces and channels for in vitro testing devices, including microfluidic chips, and materials that support vascularization such as for use in engineered tissues. The present invention includes novel methods required for the successful production of cellularized substrates, systems and components used for the same, and methods of using the resultant cell and tissue compositions.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: February 25, 2020
    Assignee: Auburn University
    Inventors: Elizabeth A. Lipke, Wen Jun Seeto
  • Patent number: 10561161
    Abstract: Comestible products, for example beverage products, are disclosed containing encapsulated probiotic bacteria having resistance to subjection to at least thermal and acidic conditions. Beverage products include at least one aqueous liquid and capsules comprising a gelled mixture of alginate and denatured protein, and probiotic bacteria entrapped within the gelled mixture. The average particle size of the capsules is optionally less than 1000 microns (?m) in diameter, such as less than 500 ?m in diameter. Methods are provided for making such encapsulated probiotics by providing a mixture comprising sodium alginate, denatured protein and active probiotic cells, and combining the mixture with a divalent cation to initiate cold gelation of the sodium alginate and denatured protein to form a second mixture. The second mixture is passed through an opening having a diameter of less than 1000 ?m to form capsules. The weight ratio of protein to alginate is from 1:1 to 9:1.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: February 18, 2020
    Assignees: Pepsico, Inc., Massey University
    Inventors: Yuan Fang, Breda Kennedy, Teodoro Rivera, Kyoung-Sik Han, Anil Kumar Anal, Harjinder Singh
  • Patent number: 10537131
    Abstract: Electrically heated cigarettes used in an electrical smoking system include a flavoring-release additive and sorbent effective to remove one or more gas-phase constituents of mainstream tobacco smoke. The flavoring-release additive includes gamma cyclodextrin and at least one flavoring. Flavoring is released in a cigarette upon the flavoring-release additive reaching at least a minimum temperature during smoking. The flavoring-release additive can have various forms including, for example, powder and films.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: January 21, 2020
    Assignee: Philip Morris USA Inc.
    Inventors: Munmaya K. Mishra, Susan E. Wrenn, Jay A Fournier
  • Patent number: 10370434
    Abstract: The invention relates to a Myc dominant negative mutant, called Omomyc, for use in medicine and for use in the prevention and/or treatment of cancer. The invention also refers to a fusion protein comprising Omomyc and pharmaceutical composition thereof and their use in medicine and, in particular, for treatment of cancer.
    Type: Grant
    Filed: May 7, 2014
    Date of Patent: August 6, 2019
    Assignee: FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON
    Inventors: Laura Soucek, Marie-Eve Beaulieu